Healio: Semaglutide Cuts Risk for Worsening Heart Failure, CV Death Among Adults with HFpEF

Semaglutide cut the risk for worsening heart failure and cardiovascular death for adults with heart failure with preserved ejection fraction, according to data presented at the European Society of Cardiology Congress and simultaneously published in The Lancet.

As Healio previously reported from the STEP-HFpEF trial, semaglutide (Ozempic/Wegovy, Novo Nordisk) was associated with improvements in HF symptom burden among adults with HFpEF and obesity. In a pooled analysis of data from STEP-HFpEF, STEP-HFpEF DM, FLOW and SELECT, all funded by Novo Nordisk, researchers observed semaglutide 1 mg or 2.4 mg reduced risk for worsening HF events and CV death compared with placebo.

“In this pooled analysis of patients with heart failure and preserved ejection fraction across the SELECT, FLOW, STEP-HFpEF and STEP-HFpEF diabetes trials, semaglutide significantly reduced the risk of cardiovascular death or worsening heart failure as compared with placebo, as well as worsening heart failure events alone, but the effects on cardiovascular death were not significant,” Mikhail Kosiborod, MD, FACC, FAHA, cardiologist at Saint Luke’s Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City School of Medicine, said during a presentation.

Read the full Healio Cardiology Today article: Semaglutide Cuts Risk for Worsening Heart Failure, CV Death Among Adults with HFpEF